

# Tuberculosis profile: Armenia

Population 2019: 3 million

## Estimates of TB burden\*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	780 (590-980)	26 (20-33)
HIV-positive TB incidence	81 (56-110)	2.8 (1.9-3.8)
MDR/RR-TB incidence**	170 (110-240)	5.8 (3.8-8.2)
HIV-negative TB mortality	1 (0-2)	0.03 (0.02-0.05)
HIV-positive TB mortality	17 (11-24)	0.57 (0.36-0.82)

## Estimated proportion of TB cases with MDR/RR-TB\*, 2019

New cases	16% (12-22)
Previously treated cases	41% (29-54)

## Universal health coverage and social protection\*


TB treatment coverage (notified/estimated incidence), 2019	80% (63-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	2% (1-4)

## TB case notifications, 2019

Total new and relapse	621
- % tested with rapid diagnostics at time of diagnosis	82%
- % with known HIV status	95%
- % pulmonary	73%
- % bacteriologically confirmed ^	59%
- % children aged 0-14 years	6%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



## HIV-negative TB mortality

(Rate per 100 000 population per year)



## Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	20%
- % men	74%
Total cases notified	670

## TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	62	10%
- on antiretroviral therapy	62	100%

## Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	97%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	100%
Laboratory-confirmed cases - MDR/RR-TB ^^	65
Patients started on treatment - MDR/RR-TB ^^	67
Laboratory-confirmed cases - XDR-TB ^^	12
Patients started on treatment - XDR-TB ^^	12
MDR/RR-TB cases tested for resistance to any fluoroquinolone	63

## Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	81%	615
Previously treated cases, excluding relapse, registered in 2018	59%	29
HIV-positive TB cases registered in 2018	64%	61
MDR/RR-TB cases started on second-line treatment in 2017	50%	104
XDR-TB cases started on second-line treatment in 2017	44%	16

## TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	2.7%
---	------



## Treatment success rate



## Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 69% (63-76)

## TB financing

National TB budget, 2020 (US\$ millions)	5
- Funding source, domestic	65%
- Funding source, international	35%
- unfunded	0%

\* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

Generated 2020-10-21 by the World Health Organization (<https://www.who.int/tb/data/>)